156 related articles for article (PubMed ID: 38646529)
1. Case report: A rare immune-related adverse effect: hepatic cavernous hemangioma induced by camrelizumab.
Zhang C; Wang G; Liu N; Li T; Zhu J; Hou H
Front Immunol; 2024; 15():1387465. PubMed ID: 38646529
[TBL] [Abstract][Full Text] [Related]
2. Reactive cutaneous capillary endothelial proliferation in advanced hepatocellular carcinoma patients treated with camrelizumab: data derived from a multicenter phase 2 trial.
Wang F; Qin S; Sun X; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Yan P; Zou J
J Hematol Oncol; 2020 May; 13(1):47. PubMed ID: 32393323
[TBL] [Abstract][Full Text] [Related]
3. Hepatic cavernous hemangioma developed in non-small cell lung cancer patients after receiving Camrelizumab treatment: two case reports.
Jin Y; Xu J; Zhuang D; Dong L; Sun Y; Zhao L; Xiao W
Front Oncol; 2023; 13():1221309. PubMed ID: 37601678
[TBL] [Abstract][Full Text] [Related]
4. Immune-Related Adverse Events Mimicking Behcet's Disease in a Gastric Cancer Patient Following Camrelizumab Treatment.
Wang D; Zhang S; Ding P; Zhao Y; Zhang X; Zhao Q
Iran J Immunol; 2020 Jun; 17(2):167-171. PubMed ID: 32602470
[TBL] [Abstract][Full Text] [Related]
5. Anlotinib improved the reactive cutaneous capillary endothelial proliferation induced by camrelizumab: a case report.
Wu R; Ju Y; Long T; Su Z; Zhu G; Liu S
Transl Cancer Res; 2022 Aug; 11(8):2940-2945. PubMed ID: 36093549
[TBL] [Abstract][Full Text] [Related]
6. The clinical application of camrelizumab on advanced hepatocellular carcinoma.
Chen Z; Lu X; Koral K
Expert Rev Gastroenterol Hepatol; 2020 Nov; 14(11):1017-1024. PubMed ID: 32762583
[TBL] [Abstract][Full Text] [Related]
7. Salvage therapy of reactive capillary hemangiomas: Apatinib alleviates the unique adverse events induced by camrelizumab in non-small cell lung cancer.
Li W; Wei Z; Yang X; Huang G; Han X; Ni Y; Wang J; Meng M; Zou Z; Wen Q; Ye X
J Cancer Res Ther; 2019; 15(7):1624-1628. PubMed ID: 31939447
[TBL] [Abstract][Full Text] [Related]
8. A case report and literature review on reactive cutaneous capillary endothelial proliferation induced by camrelizumab in a nasopharyngeal carcinoma patient.
Lin Y; Lin Y; Zhong X; Chen Q; Tang S; Chen J
Front Oncol; 2023; 13():1280208. PubMed ID: 38090483
[TBL] [Abstract][Full Text] [Related]
9. Reactive Cutaneous Capillary Endothelial Proliferation Caused by Camrelizumab: Sixteen Case Reports.
Hui-Mei P; Guang-Ming H; Xiao-Ling Q; Hong-Liang Z; Si-Jun W
Indian J Dermatol; 2023; 68(3):318-326. PubMed ID: 37529461
[TBL] [Abstract][Full Text] [Related]
10. Case Report: Successful treatment of advanced hepatocarcinoma with the PD-1 inhibitor Camrelizumab.
Ye W; Cai L; Zhang M; Wu Y; Sun H; Wang YD; Xia Y
Front Immunol; 2023; 14():1221418. PubMed ID: 37575222
[TBL] [Abstract][Full Text] [Related]
11. Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study.
Mei Q; Hu G; Yang Y; Liu B; Yin J; Li M; Huang Q; Tang X; Böhner A; Bryant A; Kurts C; Yuan X; Li J
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264438
[TBL] [Abstract][Full Text] [Related]
12. Thalidomide for prevention of camrelizumab-induced reactive cutaneous capillary endothelial proliferation.
Song G; Zhang FF; Cheng HD
Australas J Dermatol; 2022 May; 63(2):217-221. PubMed ID: 35229882
[TBL] [Abstract][Full Text] [Related]
13. Reactive cutaneous capillary endothelial proliferation following camrelizumab monotherapy or combination therapy for multi-cancers: a large-scale pooled analysis of 10 studies in China.
Qu W; Wang F; Qin S; Sun Y; Huang C
Ther Adv Med Oncol; 2024; 16():17588359241242607. PubMed ID: 38606164
[TBL] [Abstract][Full Text] [Related]
14. Experience With Anti-PD-1 Antibody, Camrelizumab, Monotherapy for Biliary Tract Cancer Patients and Literature Review.
Shen T; Zheng S; Geng L; Liu Z; Xu J; Lin B; Qian J; Zheng S
Technol Cancer Res Treat; 2020; 19():1533033820979703. PubMed ID: 33308041
[TBL] [Abstract][Full Text] [Related]
15. Camrelizumab: an investigational agent for hepatocellular carcinoma.
Xu B; Sun HC
Expert Opin Investig Drugs; 2022 Apr; 31(4):337-346. PubMed ID: 34937475
[TBL] [Abstract][Full Text] [Related]
16. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1.
Song H; Liu X; Jiang L; Li F; Zhang R; Wang P
Recent Pat Anticancer Drug Discov; 2021; 16(3):312-332. PubMed ID: 33563158
[TBL] [Abstract][Full Text] [Related]
17. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
18. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial.
Mei K; Qin S; Chen Z; Liu Y; Wang L; Zou J
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33741732
[TBL] [Abstract][Full Text] [Related]
19. Complete remission of reactive cutaneous capillary endothelial proliferation caused by the programmed cell death-1 inhibitor camrelizumab achieved through thalidomide monotherapy: A case report.
Wang C; Lei K; Jia Y; Jiang Z; Wang S
Exp Ther Med; 2023 Jul; 26(1):324. PubMed ID: 37346410
[TBL] [Abstract][Full Text] [Related]
20. Camrelizumab-induced oral lichenoid reaction with subepithelial CD4+ T-cell infiltration.
Wang X; Fu T; Sun W
J Oncol Pharm Pract; 2024 Jan; 30(1):228-234. PubMed ID: 37817675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
